Physician profile
Ivan Cvik
NPI 1578505905
$2,704.79
in general payments reported to CMS, 2019-2025
32 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $509 · 2021: $397 · 2022: $298 · 2023: $258 · 2024: $225 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $421.65 | 2019-2023 | Xeomin |
| Amgen INC. | $322.32 | 2019-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $307.33 | 2019-2025 | Wegovy |
| Galderma Laboratories, L.P. | $169.54 | 2019-2022 | |
| Abbvie INC. | $152.27 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $151.53 | 2019-2021 | |
| Allergan, INC. | $147.67 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.87 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.33 | 2022-2024 | Xifaxan |
| Insmed, INC. | $84.60 | 2019-2021 | |
| Pfizer INC. | $72.53 | 2024-2025 | |
| Esperion Therapeutics, INC. | $66.07 | 2023-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $61.01 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $60.82 | 2020-2023 | Mounjaro |
| Mvp Orthopedics INC | $55.02 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $44.04 | 2019-2020 | |
| Eisai INC. | $35.75 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $33.76 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.78 | 2022 | |
| Acella Pharmaceuticals, LLC | $31.02 | 2024-2025 | NP Thyroid 60 |
| Therapeuticsmd, INC. | $21.47 | 2019 | |
| Idorsia Pharmaceuticals US INC | $19.00 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $17.37 | 2021 | |
| Vivus LLC | $16.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.14 | 2019 | |
| Antares Pharma, INC. | $15.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.98 | 2022 | |
| Currax Pharmaceuticals LLC | $14.38 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Cvik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.